Royalty Book Value Per Share from 2010 to 2024

RPRX Stock

USD 26.60 0.31 1.18%

Royalty Pharma Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share will likely drop to 14.78 in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Royalty Pharma Plc according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

22.52963912

Current Value

14.78

Quarterly Volatility

9.26658127

Credit Downgrade

Yuan Drop

Covid

Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 196.5 M, Total Revenue of 2.5 B or Research Development of 57.5 M, as well as many indicators such as Price To Sales Ratio of 5.07, Dividend Yield of 0.0361 or PTB Ratio of 3.83. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.

Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Royalty Pharma Plc over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Royalty Pharma's Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 15.40 X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Royalty Book Value Per Share Regression Statistics

	Arithmetic Mean	14.65
	Geometric Mean	12.56
	Coefficient Of Variation	63.27
	Mean Deviation	7.01
	Median	12.62
	Standard Deviation	9.27
	Sample Variance	85.87
	Range	32.5337
	R-Value	0.68
	Mean Square Error	49.39
	R-Squared	0.47
	Significance	0.01
	Slope	1.41
	Total Sum of Squares	1,202

Royalty Book Value Per Share History

	2024	14.78
	2023	22.53
	2022	21.75
	2021	24.71
	2020	39.88
	2019	16.78
	2018	12.85

Other Fundumenentals of Royalty Pharma Plc

Tangible Book Value Per Share

Royalty Pharma Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Short Term Investments	Total Liab	Treasury Stock	Common Stock	Property Plant Equipment	Intangible Assets	Net Tangible Assets	Retained Earnings	Total Current Assets	Net Debt	Long Term Debt	Net Receivables	Long Term Debt Total	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Current Deferred Revenue	Capital Surpluse
Total Assets		0.98	0.8	0.32	0.95	-0.24	0.21	-0.36	-0.17	0.93	0.92	0.88	0.7	0.13	0.35	0.29	0.63	0.85	0.82	-0.83	-0.23	0.44	-0.39	0.6
Total Stockholder Equity	0.98		0.83	0.29	0.91	-0.25	0.26	-0.35	-0.13	0.91	0.91	0.82	0.67	0.01	0.27	0.17	0.53	0.8	0.76	-0.77	-0.27	0.32	-0.38	0.51
Accounts Payable	0.8	0.83		-0.18	0.71	-0.23	0.06	-0.25	-0.32	0.74	0.79	0.45	0.83	0.05	0.6	0.37	0.71	0.83	0.79	-0.74	-0.6	0.19	-0.74	0.71
Short Term Investments	0.32	0.29	-0.18		0.27	0.35	-0.01	-0.39	0.09	0.27	0.27	0.49	0.0	0.13	-0.5	-0.14	-0.02	0.2	0.14	-0.26	0.49	0.52	0.53	-0.15
Total Liab	0.95	0.91	0.71	0.27		-0.34	0.46	-0.37	-0.03	0.96	0.92	0.91	0.67	0.16	0.32	0.28	0.63	0.73	0.65	-0.66	-0.29	0.41	-0.32	0.54
Treasury Stock	-0.24	-0.25	-0.23	0.35	-0.34		-0.42	-0.68	0.09	-0.32	-0.3	-0.26	-0.2	0.0	-0.06	-0.04	-0.16	-0.09	-0.03	0.01	0.24	0.0	0.1	-0.07
Common Stock	0.21	0.26	0.06	-0.01	0.46	-0.42		-0.18	0.53	0.42	0.37	0.37	0.07	-0.22	-0.27	-0.27	-0.07	-0.21	-0.35	0.35	-0.31	-0.2	0.18	-0.28
Property Plant Equipment	-0.36	-0.35	-0.25	-0.39	-0.37	-0.68	-0.18		-0.3	-0.36	-0.35	-0.33	-0.26	-0.04	-0.12	-0.1	-0.23	-0.28	-0.25	0.25	0.12	-0.14	0.13	-0.2
Intangible Assets	-0.17	-0.13	-0.32	0.09	-0.03	0.09	0.53	-0.3		-0.07	-0.12	0.03	-0.34	-0.27	-0.36	-0.39	-0.4	-0.46	-0.49	0.47	0.05	-0.33	0.34	-0.47
Net Tangible Assets	0.93	0.91	0.74	0.27	0.96	-0.32	0.42	-0.36	-0.07		0.98	0.83	0.74	0.05	0.3	0.28	0.65	0.78	0.65	-0.67	-0.39	0.41	-0.26	0.6
Retained Earnings	0.92	0.91	0.79	0.27	0.92	-0.3	0.37	-0.35	-0.12	0.98		0.75	0.81	0.04	0.27	0.27	0.69	0.82	0.67	-0.68	-0.46	0.41	-0.29	0.59
Total Current Assets	0.88	0.82	0.45	0.49	0.91	-0.26	0.37	-0.33	0.03	0.83	0.75		0.37	0.19	0.15	0.18	0.38	0.58	0.58	-0.63	0.1	0.45	-0.1	0.37
Net Debt	0.7	0.67	0.83	0.0	0.67	-0.2	0.07	-0.26	-0.34	0.74	0.81	0.37		0.3	0.49	0.49	0.93	0.84	0.69	-0.66	-0.65	0.48	-0.58	0.72
Long Term Debt	0.13	0.01	0.05	0.13	0.16	0.0	-0.22	-0.04	-0.27	0.05	0.04	0.19	0.3		0.18	0.78	0.52	0.27	0.33	-0.3	0.3	0.82	-0.41	0.36
Net Receivables	0.35	0.27	0.6	-0.5	0.32	-0.06	-0.27	-0.12	-0.36	0.3	0.27	0.15	0.49	0.18		0.49	0.65	0.57	0.64	-0.57	-0.48	0.03	-0.76	0.82
Long Term Debt Total	0.29	0.17	0.37	-0.14	0.28	-0.04	-0.27	-0.1	-0.39	0.28	0.27	0.18	0.49	0.78	0.49		0.66	0.53	0.56	-0.5	0.02	0.72	-0.61	0.75
Net Invested Capital	0.63	0.53	0.71	-0.02	0.63	-0.16	-0.07	-0.23	-0.4	0.65	0.69	0.38	0.93	0.52	0.65	0.66		0.83	0.73	-0.7	-0.51	0.61	-0.63	0.84
Long Term Investments	0.85	0.8	0.83	0.2	0.73	-0.09	-0.21	-0.28	-0.46	0.78	0.82	0.58	0.84	0.27	0.57	0.53	0.83		0.95	-0.95	-0.32	0.57	-0.54	0.85
Short Long Term Debt	0.82	0.76	0.79	0.14	0.65	-0.03	-0.35	-0.25	-0.49	0.65	0.67	0.58	0.69	0.33	0.64	0.56	0.73	0.95		-0.99	-0.14	0.53	-0.63	0.85
Capital Stock	-0.83	-0.77	-0.74	-0.26	-0.66	0.01	0.35	0.25	0.47	-0.67	-0.68	-0.63	-0.66	-0.3	-0.57	-0.5	-0.7	-0.95	-0.99		0.08	-0.56	0.52	-0.81
Net Working Capital	-0.23	-0.27	-0.6	0.49	-0.29	0.24	-0.31	0.12	0.05	-0.39	-0.46	0.1	-0.65	0.3	-0.48	0.02	-0.51	-0.32	-0.14	0.08		0.3	0.4	-0.36
Short Term Debt	0.44	0.32	0.19	0.52	0.41	0.0	-0.2	-0.14	-0.33	0.41	0.41	0.45	0.48	0.82	0.03	0.72	0.61	0.57	0.53	-0.56	0.3		-0.16	0.47
Current Deferred Revenue	-0.39	-0.38	-0.74	0.53	-0.32	0.1	0.18	0.13	0.34	-0.26	-0.29	-0.1	-0.58	-0.41	-0.76	-0.61	-0.63	-0.54	-0.63	0.52	0.4	-0.16		-0.66
Capital Surpluse	0.6	0.51	0.71	-0.15	0.54	-0.07	-0.28	-0.2	-0.47	0.6	0.59	0.37	0.72	0.36	0.82	0.75	0.84	0.85	0.85	-0.81	-0.36	0.47	-0.66

Click cells to compare fundamentals

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	22.53	14.78
Tangible Book Value Per Share	22.53	13.71

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC